In a research report issued today, Roth Capital analyst Debjit Chattopadhyay reiterated a Buy rating on Alcobra Ltd (NASDAQ:ADHD) with a price target …
In a research report issued today, Roth Capital analyst Debjit Chattopadhyay maintained a Buy rating on Nektar Therapeutics (NASDAQ:NKTR) with a price target …
In a research report issued today, Roth Capital analyst Debjit Chattopadhyay reiterated a Buy rating on Nektar Therapeutics (NASDAQ:NKTR) with a $21 price target, which represents a potential upside …
In a research report published today, Roth Capital analyst Debjit Chattopadhyay reiterated a Buy rating on Alcobra Pharma (NASDAQ:ADHD), following first patient enrollment in a phase IIb study on …
In a research note released today, Roth Capital analyst Debjit Chattopadhyay reiterated coverage with a Buy rating on shares of NeoGenomics Laboratories (NEO) and a $7.00 price target, following completion of $32.
In a research report published this morning, Roth Capital analyst Debjit Chattopadhyay reiterated a Buy rating on Alcobra Pharma (NASDAQ:ADHD) with a $40 price target …
In a research note published today, Roth Capital analyst Debjit Chattopadhyay reiterated a Buy rating on Alcobra Pharma (ADHD) with a $40 price target, as the company commenced patient …
In a research report issued August 11, Roth Capital analyst Debjit Chattopadhyay reinstated a Buy rating on Nektar Therapeutics (NKTR), and introduced a $19 price target. The following …
In a research note published today, Roth Capital analyst Debjit Chattopadhyay reiterated a Buy rating on Sarepta Therapeutics (SRPT) with a $34 price target, following the appointment of John Hodgman, …
In a research note published yesterday, Roth Capital analyst Debjit Chattopadhyay reiterated a Buy rating on Sarepta Therapeutics (SRPT) with a $34 price …